

## Claims

[Claim 1]

A conjugate comprising an anti-CD26 antibody or a fragment containing an antigen-recognition site of the anti-CD26 antibody, which is linked to triptolide.

[Claim 2]

The conjugate of claim 1, wherein the anti-CD26 antibody or the fragment thereof is a humanized antibody or a fragment thereof.

10 [Claim 3]

The conjugate of claim 2, wherein the humanized antibody or the fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 to 14, and a light chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7.

20 [Claim 4]

The conjugate of claim 2, wherein the humanized antibody or the fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7, and a light chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid

sequence selected from the group consisting of SEQ ID  
NOs: 8 to 14.

[Claim 5]

5 The conjugate of claim 2, wherein the humanized  
antibody or the fragment thereof comprises at least one  
heavy chain comprising an amino acid sequence having 90%  
or more sequence identity to the amino acid sequence of  
SEQ ID NO: 17, and at least one light chain comprising an  
amino acid sequence having 90% or more sequence identity  
10 to the amino acid sequence of SEQ ID NO: 18.

[Claim 6]

The conjugate of claim 2, wherein the humanized  
antibody or the fragment thereof comprises at least one  
heavy chain comprising an amino acid sequence from  
15 position 20 to position 465 of the amino acid sequence of  
SEQ ID NO: 17, and at least one light chain comprising an  
amino acid sequence from position 21 to position 234 of  
the amino acid sequence of SEQ ID NO: 18.

[Claim 7]

20 The conjugate of any one of claims 2 to 6, wherein  
the humanized antibody or the fragment thereof binds to  
one or more peptides selected from the group consisting  
of SEQ ID NOs: 19 to 28.

[Claim 8]

25 The conjugate of claim 2, wherein the humanized  
antibody is produced by a strain designated as

s604069.YST-pABMC148 (x411) under deposition No. PTA-7695  
of the American Type Culture Collection (ATCC).

[Claim 9]

The conjugate of any one of claims 1 to 8, wherein  
5 the fragment is selected from the group consisting of Fab,  
Fab', Fab'-SH, Fv, scFv, and F(ab')<sub>2</sub>.

[Claim 10]

A pharmaceutical composition comprising a conjugate  
of any one of claims 1 to 9 as an active ingredient.

10 [Claim 11]

The pharmaceutical composition of claim 10 for the  
treatment of malignant mesothelioma.

[Claim 12]

A malignant mesothelioma cell growth inhibitor  
15 comprising a conjugate of any one of claims 1 to 9.

[Claim 13]

A malignant mesothelioma cell lysing agent  
comprising a conjugate of any one of claims 1 to 9.

[Claim 14]

20 Use of a conjugate of any one of claims 1 to 9 in  
the manufacture of a pharmaceutical composition for the  
treatment of malignant mesothelioma.

[Claim 15]

A pharmaceutical composition comprising an anti-CD26  
25 antibody or a fragment containing an antigen-recognition  
site of the anti-CD26 antibody, and gemcitabine.

[Claim 16]

The pharmaceutical composition of claim 15, wherein the anti-CD26 antibody or the fragment thereof is a humanized antibody or a fragment thereof.

[Claim 17]

5       The pharmaceutical composition of claim 16, wherein the humanized antibody or the fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid sequence selected from the group consisting of SEQ ID  
10   NOs: 8 to 14, and a light chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 7.

[Claim 18]

15       The pharmaceutical composition of claim 16, wherein the humanized antibody or the fragment thereof comprises a heavy chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid sequence selected from the group consisting of SEQ ID  
20   NOs: 1 to 7, and a light chain variable region comprising an amino acid sequence having 80% or more identity to an amino acid sequence selected from the group consisting of SEQ ID NOs: 8 to 14.

[Claim 19]

25       The pharmaceutical composition of claim 16, wherein the humanized antibody or the fragment thereof comprises at least one heavy chain comprising an amino acid

sequence having 90% or more sequence identity to the amino acid sequence of SEQ ID NO: 17, and at least one light chain comprising an amino acid sequence having 90% or more sequence identity to the amino acid sequence of  
5 SEQ ID NO: 18.

[Claim 20]

The pharmaceutical composition of claim 16, wherein the humanized antibody or the fragment thereof comprises at least one heavy chain comprising an amino acid  
10 sequence from position 20 to position 465 of the amino acid sequence of SEQ ID NO: 17, and at least one light chain comprising an amino acid sequence from position 21 to position 234 of the amino acid sequence of SEQ ID NO: 18.

15 [Claim 21]

The pharmaceutical composition of claim 16, wherein the humanized antibody or the fragment thereof binds to one or more peptides selected from the group consisting of SEQ ID NOs: 19 to 28.

20 [Claim 22]

The pharmaceutical composition of claim 16, wherein the humanized antibody is produced by a strain designated as s604069.YST-pABMC148 (x411) under deposition No. PTA-7695 of the American Type Culture Collection (ATCC).

25 [Claim 23]

The pharmaceutical composition of any one of claims 15 to 22, wherein the fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, and F(ab')<sub>2</sub>.

[Claim 24]

5       The pharmaceutical composition of any one of claims 15 to 23 for the treatment of malignant mesothelioma.

[Claim 25]

A malignant mesothelioma cell growth inhibitor comprising a pharmaceutical composition of any one of  
10       claims 15 to 23.

[Claim 26]

A malignant mesothelioma cell lysing agent comprising a pharmaceutical composition of any one of claims 15 to 23.

15       [Claim 27]

Use of an anti-CD26 antibody and gemcitabine in the manufacture of a pharmaceutical composition for the treatment of malignant mesothelioma.